CD47 and neoplasm: Similarly, detachable immune liposomes loaded with paclitaxel and anti-CD47 antibody have been developed for targeted chemotherapy against TNBC, resulting in improved antitumor efficacy against TNBC and inhibited tumor recurrence (70).